NO20001238D0 - Monoklonalt antistoff som induserer apoptose - Google Patents

Monoklonalt antistoff som induserer apoptose

Info

Publication number
NO20001238D0
NO20001238D0 NO20001238A NO20001238A NO20001238D0 NO 20001238 D0 NO20001238 D0 NO 20001238D0 NO 20001238 A NO20001238 A NO 20001238A NO 20001238 A NO20001238 A NO 20001238A NO 20001238 D0 NO20001238 D0 NO 20001238D0
Authority
NO
Norway
Prior art keywords
antibody
monoclonal antibody
associated proteins
human integrin
apoptosis
Prior art date
Application number
NO20001238A
Other languages
English (en)
Other versions
NO20001238L (no
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20001238D0 publication Critical patent/NO20001238D0/no
Publication of NO20001238L publication Critical patent/NO20001238L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20001238A 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose NO20001238L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11
PCT/JP1998/004118 WO1999012973A1 (fr) 1997-09-11 1998-09-11 Anticorps monoclonal induisant l'apoptose

Publications (2)

Publication Number Publication Date
NO20001238D0 true NO20001238D0 (no) 2000-03-09
NO20001238L NO20001238L (no) 2000-05-11

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001238A NO20001238L (no) 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose

Country Status (14)

Country Link
US (1) US20030157100A1 (no)
EP (1) EP1035132B1 (no)
KR (2) KR20040106585A (no)
CN (1) CN1198845C (no)
AT (1) ATE395362T1 (no)
AU (1) AU740225B2 (no)
CA (1) CA2303072A1 (no)
DE (1) DE69839492D1 (no)
HU (1) HUP0003513A3 (no)
NO (1) NO20001238L (no)
PL (1) PL339265A1 (no)
RU (1) RU2212413C2 (no)
SK (1) SK3232000A3 (no)
WO (1) WO1999012973A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046314C (zh) * 1993-09-03 1999-11-10 中外制药株式会社 具有引起细胞程序性死亡的特征的单克隆抗体
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
WO2000053634A1 (fr) * 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
WO2001079494A1 (fr) * 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
KR20030055274A (ko) 2000-10-20 2003-07-02 츄가이 세이야꾸 가부시키가이샤 저분자화 트롬보포에틴 아고니스트 항체
KR100870123B1 (ko) * 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
CA2424371A1 (en) * 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Agonistic monoclonal antibody fragments
CA2424364A1 (en) * 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Degraded tpo agonist antibody
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
DE60324700D1 (de) 2002-10-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1609803A4 (en) * 2003-03-31 2006-05-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODY AGAINST CD22 AND ITS USE
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
CN101133083A (zh) * 2003-11-11 2008-02-27 中外制药株式会社 人源化的抗cd47抗体
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
WO2005056603A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
PE20081004A1 (es) * 2006-07-13 2008-09-18 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
WO2009091547A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
DK3056515T3 (da) 2008-01-15 2019-07-01 Univ Leland Stanford Junior Fremgangsmåder til at manipulere fagocytose medieret af cd47
CA2732102C (en) 2008-08-07 2018-01-02 Jeffrey S. Isenberg Radioprotectants targeting thrombospondin-1 and cd47
HUE13746964T2 (hu) * 2012-02-06 2020-01-28 Inhibrx Inc CD47 antitestek és alkalmazási eljárásaik
EP2931751B1 (en) 2012-12-12 2020-02-05 Arch Oncology, Inc. Therapeutic cd47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
BR112020009805A2 (pt) 2017-12-01 2020-10-13 Seattle Genetics, Inc. antígeno do mesmo que liga especificamente cd47 humano, o anticorpo ou fragmento de ligação a antígeno, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos para produzir o anticorpo ou fragmento de ligação a antígeno, para tratar um câncer que expressa cd47 num indivíduo e para induzir apoptose de uma célula que expressa cd47, e, anticorpo mascarado
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
WO2023076511A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods of generating cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690528B2 (en) * 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CN1046314C (zh) * 1993-09-03 1999-11-10 中外制药株式会社 具有引起细胞程序性死亡的特征的单克隆抗体
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU2232597A (en) * 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
ATE395362T1 (de) 2008-05-15
CA2303072A1 (en) 1999-03-18
WO1999012973A1 (fr) 1999-03-18
SK3232000A3 (en) 2000-09-12
HUP0003513A3 (en) 2004-05-28
AU9002898A (en) 1999-03-29
HUP0003513A2 (hu) 2001-02-28
DE69839492D1 (de) 2008-06-26
AU740225B2 (en) 2001-11-01
EP1035132B1 (en) 2008-05-14
KR20040106585A (ko) 2004-12-17
RU2212413C2 (ru) 2003-09-20
KR20010023866A (ko) 2001-03-26
EP1035132A4 (en) 2005-02-09
NO20001238L (no) 2000-05-11
CN1276798A (zh) 2000-12-13
CN1198845C (zh) 2005-04-27
EP1035132A1 (en) 2000-09-13
PL339265A1 (en) 2000-12-04
US20030157100A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
NO20001238D0 (no) Monoklonalt antistoff som induserer apoptose
FI960567A0 (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
ATE123652T1 (de) Antigene.
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
PT921395E (pt) Ensaio para medicao de fragmentos de proteina em meios biologicos
DE69228701T2 (de) Fragmente von Prion Proteinen.
FI955798A0 (fi) Terapeuttiset vasta-ainefrangmentit
PT733069E (pt) Antigenios ctla-8 de primata purificados e reagentes relacionados
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ES2133738T3 (es) Metodo para cuantificar lbp en fluidos corporales.
DE3872754T2 (de) Nachweis von antikoerpern humaner immundefizienz-viren.
DE3854553T2 (de) Verfahren zum schnellen und empfindlichen Nachweis von IgM-Antikörpern gegen retrovirale Antigene.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
DE69504959T2 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE59505585D1 (de) Antigene und Antikörper zum Nachweis von Kollagen I
BR9903250A (pt) Antìgenos e imunoanálises para diagnóstico da doença de chagas.
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
PT744027E (pt) Utilizacao de metodos para identificar oligopeptidos de sinal hidrofilicos
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.
ATE192236T1 (de) Menschliche phospholipase aktivierender proteinteil
DE69533904D1 (de) Chemische Modifikation von Antikörpern und Antigenen
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.